F.01
Safety Signals
Adverse events extracted, classified by severity, and rated by evidence weight — pooled from regulators and the peer-reviewed literature.
ADRs cause 6.5% of hospital admissions — most are preventablePirmohamed et al. · BMJ 329:15
Know before you prescribe.
Drug safety signals, interactions, dosing, and Africa formulary status — any drug, any patient, in under sixty seconds. Built on eleven million papers and live regulatory feeds, written for the bedside.
0M+
Papers indexed
PubMed · medRxiv · PMC
0K+
FDA documents
FAERS · MedWatch · labels
<0s
Per full scan
From query to clinical brief
0
African regulators
NAFDAC · SAHPRA · WHO PQ
§ 01 — Features
01.
Nine instruments. One scan. One brief.
Every signal that matters — safety, dosing, interactions, formulary — surfaced in parallel and cross-referenced against the literature, the trials registry, and the regulators that ship in your market.
F.01
Safety Signals
Adverse events extracted, classified by severity, and rated by evidence weight — pooled from regulators and the peer-reviewed literature.
F.02
Rising Signal Detection
Publication velocity tracked at 30 days versus the trailing six-month baseline. New safety concerns flagged before they reach the label.
F.03
Trial Cross-Reference
Active ClinicalTrials.gov studies pulled in and flagged against open signals — including trials marked for immediate safety review.
F.04
Safety Scorecard
Therapeutic alternatives ranked head-to-head on a single, source-cited score from zero to one hundred — class-aware, indication-aware.
F.05
Drug–Drug Interactions
Severity-ranked pairings with proposed mechanism, expected timing, and clinical management — not a wall of yellow warnings.
F.06
Dosage Calculator
Patient-specific dosing with renal, hepatic, body-surface-area, and weight adjustments — and the citation behind each rule.
F.07
Special Populations
Pregnancy, lactation, geriatric, and paediatric considerations surfaced as first-class flags — with the FDA category and the trial evidence behind it.
F.08
Pharmacogenomics
Gene–drug interactions read against CPIC and PharmGKB — flagged for the metabolisers and HLA variants most likely to matter at the bedside.
F.09
Africa Formulary
Registration, prequalification, and market availability checked against NAFDAC, SAHPRA, and the WHO list — the data your hospital pharmacy actually uses.
i.
Query
Type a drug, an INN, or paste a list. Add co-medications, renal function, weight, and any flags that matter.
ii.
Scan
Eleven million papers, 225K FDA documents, and live WHO, NAFDAC, and SAHPRA feeds — read in parallel.
iii.
Score
Signals classified, weighted by evidence, and ranked against therapeutic alternatives in the same class.
iv.
Brief
One source-cited clinical brief, exportable as PDF, written for the bedside — not the literature.
§ 02 — Sample brief
02.
A scan that reads like a registrar's note.
One query, one document. Severity on the left, the finding in the middle, the source on the right. No tabs. No PDFs to chase.
Critical
Thyroid C-cell tumour signal under active review — contraindicated in personal or family MTC history.
FDA · medRxiv ×3.5
High
Delayed gastric absorption may prolong warfarin Tmax — monitor INR weekly for 4 weeks after initiation.
PMC · 6 trials
Moderate
Renal-adjusted starting dose 0.25 mg weekly (eGFR <30) — no hepatic adjustment required.
FDA label · CPIC
Alternative
Tirzepatide scores 70 / 100 vs semaglutide 55 / 100 in matched class — weigh against availability.
Scorecard · 18 RCTs
Formulary
Registered with NAFDAC · WHO prequalified · SAHPRA pending — last verified today, 11:00 WAT.
NAFDAC · WHO · SAHPRA
§ 03 — From the continent, for the continent
Built for Africa's clinicians first.
A clinician in Lagos, Nairobi, or Accra monitoring drug safety manually checks FDA, WHO, NAFDAC, and SAHPRA across separate browser tabs — and still misses the rising signal. Vigil does it in one scan, cites every source, and writes the brief in the time it takes to read the chart.
NAFDACSAHPRAWHO PrequalificationAfrican market availability
A drug safety signal nobody reads is a drug safety signal nobody acts on.Editorial principle · Vigil, vol. i